With Sarepta in its sights, PepGen prices IPO to fund DMD trialsnews2022-05-06T11:16:46+00:00May 6th, 2022|FierceBiotech|
Bye-bye: Xencor culls 2 bispecifics after early-phase solid tumor data underwhelmnews2022-05-06T10:14:39+00:00May 6th, 2022|FierceBiotech|
Orion aims to challenge Vertex with new pain management licensing dealnews2022-05-06T10:02:27+00:00May 6th, 2022|FierceBiotech|
After layoffs, BridgeBio turns to dealmaking for up to 6 drugsnews2022-05-05T18:20:50+00:00May 5th, 2022|FierceBiotech|
Chutes & Ladders—Biogen CEO Vounatsos steps down amid company overhaul following Aduhelm blundernews2022-05-05T17:26:25+00:00May 5th, 2022|FierceBiotech|
Intellia puts pedal to the metal as 3 new candidates prepped for clinicnews2022-05-05T14:26:39+00:00May 5th, 2022|FierceBiotech|
BioCryst’s voluntary pause turns FDA-hold as investigation reveals likely culprit behind safety signalsnews2022-05-05T14:21:59+00:00May 5th, 2022|FierceBiotech|
Big pharma resisting temptation for biotech M&A spree until prices drop furthernews2022-05-05T13:53:42+00:00May 5th, 2022|FierceBiotech|
Bavarian Nordic’s COVID-19 vaccine holds up against omicron in phase 2, fueling pivotal booster pushnews2022-05-05T12:54:33+00:00May 5th, 2022|FierceBiotech|
Jazz flexes deal chops, paying Sumitomo $50M for ex-Asia rights to early-phase narcolepsy prospectnews2022-05-05T12:05:34+00:00May 5th, 2022|FierceBiotech|
